Glycoprotein IIb/IIIa receptor antagonist tirofiban inhibits thrombin generation during cardiopulmonary bypass in baboons

Thrombosis and Haemostasis

Volumn 82, Issue 1, 1999, Pages 140-144

  Rao, A Koneti ^a,c   Sun, Ling ^a   Hiramatsu, Yugi ^b   Gorman III, Joseph H ^b   Edmunds Jr , L Henry ^b  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; PROTAMINE; PROTHROMBIN; THROMBIN; THROMBIN ANTITHROMBIN COMPLEX; TIROFIBAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BABOON; CARDIOPULMONARY BYPASS; CONTROLLED STUDY; DRUG INFUSION; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; PRIORITY JOURNAL; THROMBIN TIME; THROMBOCYTE AGGREGATION INHIBITION;

EID: 0032785225     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1614643     Document Type: Article

References (24)

1. Walsh PN. Platelet-coagulant protein interactions, In: Hemostasis and Thrombosis. Basic Principles and Clinical Practice. Colman RW, Hirsh J. Marder VJ, eds. Philadelphia: J. B. Lippincott 1994; 629-51.
2. Mann KG, Krishnaswamy S, Lawson JH. Surface-dependent hemostasis, Semin Hematol 1992; 29: 213-26.
3. Walsh PN, Camp E, Dende D. Different requirements for intrinsic factor-Xa forming activity and platelet factor 3 activity and their relationship to platelet aggregation and secretion. Br J Haematol 1978; 40: 311-31.
4. Moorehead MT, Westengard JC, Bull BS. Platelet involvement in the activated coagulation time of heparinized blood. Anesth Analg 1984; 63: 394-6.
5. Kyrle PA, Westwick J, Scully MF, Kakkar VV, Lewis GP. Investigation of the interaction of blood platelets with the coagulation system at the site of plug formation in vivo in man-effect of low-dose aspirin. Thromb Haemost 1987; 57: 62-6.
6. Hampton KK, Cerletti C, Loizou LA, Bucchi F, Donati MB, Davies JA, de Gaetano G, Prentice CR. Coagulation, fibrinolytic and platelet function in patients on long-term therapy with aspirin 300 mg or 1,200 mg daily compared with placebo. Thromb Haemost 1990; 64: 17-20.
7. Szczeklik A, Krzanowski M, Gora P, Radwan J. Antiplatelet drugs and generation of thrombin in clotting blood. Blood 1992; 80: 2006-11.
8. Ratnatunga CP, Edmondson SF, Rees GM, Kovacs IB. High-dose aspirin inhibits shear-induced platelet reaction involving thrombin generation. Circulation 1992; 85: 1077-82.
9. Yasu T, Oshima S, Imanishi M, Nonogi H, Haze K, Kuramochi M, Omae T, Hayashi Y, Yamamoto S. Effects of aspirin DL-lysine on thrombin generation in unstable angina pectoris. Am J Cardiol 1993; 71: 1164-68.
10. Andreotti F, Davies GJ, Ujang SB, Sritara P, Kluft C, Maseri A. High-dose aspirin, thrombin, and coronary angioplasty (Letter). Lancet 1993; 341: 1161.
11. Kessels H, Beguin S, Andree H, Hemker HC. Measurement of thrombin generation in whole blood - the effect of heparin and aspirin. Thromb Haemost 1994; 72: 78-83.
12. Moliterno DJ, Califf RM, Aguirre FV, Anderson K, Sigmon KN, Weisman HF, Topol EJ. Effect of platelet glycoprotein IIb/IIIa integrin blockade on activated clotting time during percutaneous transluminal coronary angioplasty or directional atherectomy (the EPIC trial). Evaluation of c7E3 Fab in the Prevention of Ischemic Complications trial. Am J Cardiol 1995; 75: 559-62.
13. Reverter JC, Beguin S, Kessels H, Kumar R, Hemker, HC, Coller BS. Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and "clinical restenosis". J Clin Invest 1996; 98: 863-74.
14. Szczeklik A, Musial J, Undas A, Swadzba J, Gora PF, Piwowarska W, Duplaga M. Inhibition of thrombin generation by aspirin is blunted in hypercholesterolemia. Arterioscler Thromb Vasc Biol 1996; 16: 948-54.
15. Musial J, Radwan J, Szczeklik A. Aspirin delays thrombin generation in vitro through interaction with platelet phospholipids. Thromb Res 1997; 85: 367-68.
16. 3 binds prothrombin and influences its activation. J Biol Chem 1997; 272: 27183-88.
17. Gorman JH 3rd, Edmunds LH Jr. Blood anesthesia for cardiopulmonary bypass. J Card Surg 1995; 10: 270-79.
18. Brister SJ, Ofosu FA, Buchanan MR. Thrombin generation during cardiac surgery: is heparin the ideal anticoagulant? Thromb Haemost 1993; 70: 259-62.
19. Edmunds LH Jr. Extracorporeal perfusion. In: Cardiac Surgery in the Adult. Edmunds LH Jr, ed. New York: McGraw-Hill Publishing Co. 1997; 155-94.
20. Hiramatsu Y, Gikakis N, Anderson HL 3rd, Gorman JH 3rd, Marcinkiewicz C, Gould RJ, Niewiarowski S, Edmunds LH Jr. Tirofiban provides "platelet anesthesia" during cardiopulmonary bypass in baboons. J Thorac Cardiovasc Surg 1997; 113: 182-93.
21. Gould RJ, Chang CTC, Lynch RJ. MK-383 is a potent non-peptide mimic of RGD that inhibits glycoprotein IIb/IIIa. Thromb Haemost 1993; 69: 976.
22. Peerlinck K, Lepeleire ID, Goldberg M, Farrell D, Barrett J, Hand E, Panebianco D, Deckmyn H, Vermylen J, Arnout J. MK-383 (L-700,462), a selective nonpeptide platelet glycoproein IIb/IIIa antagonist, is active in man. Circulation 1993; 88: 1512-17.
23. van Willigen G, Akkerman JWN. Protein kinase C and cAMP regulate reversible exposure of binding sites for fibrinogen on glycoprotein IIb-IIIa complex of human platelets. Bioch J 1991; 273: 115-20.
24. Schwartz SM. Serum-derived growth factor is thrombin? J Clin Invest 1993; 91-3.